Incidence and Impact of Patient-Prosthesis Mismatch in Isolated Aortic Valve Surgery

Selman Dumani², Ermal Likaj, Andi Kacani, Laureta Dibra, Elizana Petrela, Vera Beca, Ali Refatllari

²Service of Cardiac Surgery, University Hospital Center “Mother Theresa”, Tirana, Albania; ²Service of Statistics, University Hospital Center “Mother Theresa”, Tirana, Albania; ³Obstetrics and Gynecology Hospital “Queen Geraldine”, Tirana, Albania

Abstract

AIM: The main topics of this work are the incidence of patient-prosthesis mismatch and the influence in the early results of isolated aortic valve surgery.

METHODS: In 193 patients isolated aortic valve surgery was performed. The study population was divided in three subgroups: 20 patients with severe, 131 patients with moderate and 42 patients without patient-prosthesis mismatch. The indexed effective orifice area was used to define the subgroups. Operative mortality and perioperative complications were considered the indicators of the early results of aortic valve surgery.

RESULTS: The incidence of severe and moderate patient-prosthesis mismatch was respectively 10.3% and 67.8%. Hospital mortality and perioperative complications were: mortality 5% vs. 3.1% vs. 2.4% (p = 0.855); low cardiac output 5% vs. 6.9% vs. 4.8% (p = 0.861); pulmonary complications 5% vs. 3.1% vs. 0.0% (p = 0.430); exploration for bleeding 5% vs. 0.8% vs. 2.4% (p = 0.319); atrial fibrillation 30% vs. 19.8% vs. 11.9% (p = 0.225); wound infection 5% vs. 0.8% vs. 0.00% (p = 0.165), respectively for the group with severe, moderate and without patient-prosthesis mismatch.

CONCLUSIONS: Patient-prosthesis mismatch is a common occurrence in aortic valve surgery. This phenomenon does not affect the early results of aortic valve surgery.

Introduction

Patient prosthesis mismatch (PPM) is one of the most controversial issues related to the aortic valve replacement. It is introduced in 1978 by Rahimtoola as a condition in which the effective prosthetic valve area, after insertion into the patient, is less than that of a normal human valve [1]. There are two main occurrence factors of PPM:

a) Effective orifice area “in vivo” and “in vitro” of the prosthesis; and

b) The patient’s small native valve annulus.

In practical terms, to define PPM currently, the most used parameter is prosthetic effective orifice surface area indexed with the patient’s body surface (EOAi). Based on this index, threshold for the appearance of PPM is 0.85 cm²/m². Patient prosthesis mismatch has been classified as moderate when 0.65 cm²/m² ≤ EOAI ≤ 0.85 cm²/m² and severe when EOAI < 0.65 cm²/m².

Patient-prosthesis mismatch is a common occurrence after aortic valve replacement. The reported prevalence of moderate PPM varies between 20–70%, whereas that of severe PPM is between 2% and 11% [2]. Nowadays, the discussion is still open about the impact of this phenomenon in the results of this kind of surgery.

The mains topics of this work are the incidence of patient-prosthesis mismatch in aortic valve surgery and the influence of these findings in the early results.
Materials and Methods

Our study was a prospective and retrospective study. All patients underwent isolated aortic valve surgery from January 2010 to January 2015 in two cardiac surgery centres, public and non-public, in Tirana (Service of Cardiac Surgery, UHC “Mother Theresa” and German Hospital). Patients who had additional surgical procedures were excluded from the study. Demographic data, intervention and postoperative data were collected from hospital records in the statistics office. Preoperative evaluation of risk of intervention was made according to EUROSCORE [5]. Surgical indication for aortic valve surgery was decided according to ESC and AHA/ACC guidelines [6, 7]. Indexed effective orifice area was used to define the degree of PPM. The effective orifice area of the prosthesis was taken from the reference prosthesis tables [2-4] while BSA was calculated according Du Bois and Du Bois formula. The body mass index was also recorded, which was calculated according to the metric formula (kg/m²).

Continuous data were presented at the mean value ± standard deviation and standard error. Differences between the two groups for continuous quantitative variables were performed by ANOVA test one way, the Bonferoni procedure. Differences between groups for discrete variables were performed by Chi-Square test. Relations between variables were analyzed through Pearson correlation coefficient (for quantitative variables) and Kendall’s Tau (for discrete variables). Presentation of the data was performed through simple and composed tables, as well as graphics like scatter diagram, bar-diagram and Box-plot. Data analysis was performed with SPSS statistical package, version 20, (Statistical Package for Social Sciences). It was considered significant values of p ≤ 0.05.

Results

Patients

In the study were included 193 patients that performed isolated aortic valve surgery. Patients were divided into three groups according to the degree of PPM: 20 patients with severe PPM; 131 patients with moderate PPM; and 42 patients without PPM.

General demographic and clinical data are presented in Table 1.

The mean population’s age was 59.53 ± 12.73. Groups with PPM had significant higher mean age comparing to other groups; 124 patients (64.6%) were males. The incidence of co morbidities was without significant statistical differences among groups except diabetes mellitus and arterial hypertension that predominate in the group with the moderate PPM. BMI was importantly greater in groups with PPM. There were no significant differences in the preliminary calculation of intervention risk.

Table 1: General demographic and clinical data

| General Data | Groups PPM | Value p |
|--------------|------------|---------|
|              | MPP severe | MPP moderate | No MPP | Total |         |
|              | n=20       | n=131     | n=42   | 193   |         |
| Age          | 63.5±11.97 | 60.4±12.47 | 54.8±12.83 | 59.5±12.73 | 0.012  |
| BMI          | 21.9±3.75  | 23.9±3.27  | 23.8±3.47 | 24.9±2.47 | 0.017  |
| BSA          | 1.85±0.13  | 1.79±0.16  | 1.75±0.20 | 1.79±0.17 | 0.10   |
| Gender       |            |            |        |       |         |
| M            | 90         | 83         | 33     | 123   |        |
| F            | 110        | 87         | 92     | 287   | 0.023  |
| Admission    |            |            |        |       |         |
| urgent       | 0.00%      | 0.00%      | 0.00%  | 0.00% | 0.00%  |
| planned      | 100.00%    | 99.90%     | 93.90% | 92.80% | 0.583  |
| NYHA II      | 6          | 32         | 6      | 44    | 0.005  |
| III          | 7          | 90         | 17     | 124   |        |
| IV           | 60.00%     | 69.20%     | 82.90% | 71.20% | 0.345  |
| HT           | 8.00%      | 64.90%     | 47.60% | 62.70% | 0.032  |
| DM           | 30.00%     | 10.70%     | 2.40%  | 10.30% | 0.005  |
| AP           | 0.00%      | 0.00%      | 0.00%  | 0.00% | 1.00%  |
| Smoking      | 20.00%     | 11.50%     | 23.80% | 15.00% | 0.12   |
| COPD         | 5.00%      | 3.80%      | 0.00%  | 3.10% | 0.406  |
| Ese Stand    | 4.90±1.66  | 4.23±2.19  | 4.03±2.33 | 4.23±2.18 | 0.554  |
| Ese Log      | 4.37±2.90  | 4.14±2.23  | 4.10±3.34 | 4.15±3.13 | 0.984  |

BMI-body mass index; BSA-body surface area; HT-hypertension; DM-diabetes mellitus; AP-peripheral arteriopathi; COPD-chronic obstructive pulmonary diseases; Ese-Stand/Log-euro score standard logistic.
Transthoracic echocardiography and transesophageal echocardiography were the main diagnostic tools. There were 121 patients (62.7%) with pure aortic stenosis; 44 patients (22.8%) with aortic insufficiency and the rest of the patients (had mixed pathology of aortic valve (28 pt. 14.5%)). Echocardiography data were presented in the Table 2.

Table 2: Echocardiography data

| Data                  | PPM severe | MPP moderate | No MPP | Total | Value p |
|-----------------------|------------|--------------|--------|-------|---------|
| EF                   | 62.4±18.12 | 59.8±10.37   | 59.9±8.10 | 60 | 0.623   |
| Anatomy              |            |              |        |       |         |
| Normal               | 18         | 100          | 32     | 156   |         |
| (9%)                 | 82.6%      | 80%          | 82.9%  |       |         |
| Bicuspide            | 2          | 21           | 8      | 37    |         |
| 10.00%               | 17.40%     | 20.00%       | 17.10% | 0.621 |         |
| As Val Stenotic      | 18         | 83           | 20     | 121   |         |
| 90.00%               | 63.36%     | 47.62%       | 62.69% |       |         |
| Regurgit             | 1          | 28           | 15     | 44    |         |
| 5.00%                | 21.37%     | 35.71%       | 28.80% |       |         |
| Calculated Annulus   | 85.00%     | 66.7%        | 51.3%  | 65.4% | 0.031   |
| Th-PW                | 12.8±20.99 | 13.2±12.02   | 12.5±3.98 | 13.0±14.94 | 0.222 |
| Ths                  | 14.0±6.11  | 14.3±6.15    | 13.5±5.82 | 14.1±5.10 | 0.129  |
| LV-TDD               | 53.7±46.77 | 57.7±48.20   | 59.7±3.76 | 57.7±48.31 | 0.107  |
| LV-TSD               | 34.0±8.71  | 39.6±9.05    | 39.4±4.40 | 39.1±9.19 | 0.123  |
| Max Val grad         | 87.7±16.78 | 88.7±20.20   | 88.4±18.58 | 88.5±19.31 | 0.963  |
| Mean Val grad        | 48.3±10.84 | 52.4±13.77   | 55.6±7.41 | 52.4±12.55 | 0.220  |

EF—ejection fraction; As Val-aortic valve; Th-PW—thickness of posterior wall; Ths—thickness of septum LV-TDD—left ventricle telesistolic diameter; LV-TSD—left ventricle telesistolic diameter; Max Val grad-maximal aortic valve gradient; Mean Val grad-mean aortic valve gradient

The echocardiography data showed that aortic stenosis was the dominant pathology (121/193 pt. 62.7 %) in our population and annular calcification is encountered much more often in the PPM groups.

Incidence of patient-prosthesis mismatch: incidence of severe PPM was 10.3% (20/193), and incidence of moderate PPM was 67.8% (131/193).

Early mortality and postoperative complications: overall mortality was 3.1% (6/193); mortality of the group with severe PPM was 5% (1/20 pt); mortality of the group with moderate PPM was 3.1% (4/131 pt); and mortality of the group without PPM was 2.4 % (1/42 pt).

We can see that in absolute value, mortality in the groups with PPM is higher but this difference is not statistically significant (p = 0.855). The incidence of postoperative complications respectively for the group with severe PPM, moderate and without PPM was: low cardiac output 5% vs. 6.9% vs. 4.8%; pulmonary complications 5% vs. 3.1 vs. 0.0%; bleeding 5% vs. 0.8% vs. 2.4%; atrial fibrillation 30% vs. 19.8% vs. 11.9%; wound infection 5% vs. 0.8% vs. 0.0%; ventricular arrhythmias 5% vs. 4.6% vs. 9.5%; conduction disturbances 10% vs. 6.9 % vs. 11.9 %;

There is a trend towards higher frequency of complications in the groups with PPM but the differences did not reach statistical significances (Table 3).

Table 3: Mortality and postoperative complications

| Morality and complications | PPM severe | MPP moderate | No PMP | Groups PPM | Total n=193 | Value p |
|---------------------------|------------|--------------|--------|------------|-------------|---------|
| Morality                  | 1          | 4            | 1      | 6          | 0.855       |         |
| Mortality                 | 5.00%      | 3.10%        | 2.40%  | 3.10%      |             |         |
| LCO                       | 1          | 9            | 2      | 12         |             |         |
| Stroke                    | 5.00%      | 6.90%        | 4.80%  | 6.20%      | 0.861       |         |
| Pulmonary                 | 0.00%      | 0.80%        | 0.00%  | 0.50%      | 0.788       |         |
| RI                        | 0.00%      | 0.80%        | 0.00%  | 2.60%      | 0.430       |         |
| Bleeding                  | 5.00%      | 8.00%        | 2.40%  | 1.00%      | 0.593       |         |
| VA                        | 6          | 6            | 4      | 11         |             |         |
| AF                         | 30.00%     | 19.80%       | 11.90% | 19.20%     | 0.225       |         |
| Wound inf                 | 5.00%      | 0.80%        | 0.00%  | 1.00%      | 0.165       |         |
| Cond Dist                 | 10.00%     | 6.90%        | 11.90% | 8.30%      | 0.564       |         |

LCO—low cardiac output; RI—renal insuficiency; VA—ventricular arrhythmias; AF—atrial fibrillation infusion; Cond Dist—conduction disturbances.

Postoperative times in intensive care unit and hospital stay are longer in the group with PPM but the difference is not important. The mean prosthesis number used is 21.59 ± 1.88. It is clear the significant difference of mean prosthesis number between groups (p < 0.001). The maximal prosthesis gradient of the PPM groups are much higher in comparison with the group without PPM (p = 0.022) (Table 4).

Table 4: Intervention and postoperative data

| Intervention and postoperative data | PPM severe | MPP moderate | No PMP | Groups PPM | Total n=193 | Value p |
|-------------------------------------|------------|--------------|--------|------------|-------------|---------|
| CPB                                 | 92.2±19.42 | 86.5±24.67   | 88.2±23.93 | 88 | 0.379       |
| IT                                  | 76.2±7.27  | 68.3±22.42   | 66.7±21.84 | 67.0±22.51 | 0.163       |
| Resp Ass                            | 42.6±10.74 | 19.8±57.37   | 11.2±57.98 | 20.4±59.53 |             |         |
| ICU Stay (h)                        | 97.9±13.9  | 65.8±10.1    | 51.1±26.24 | 65.9±9.6   | 0.202       |
| Hos Day (d)                         | 11.6±7.25  | 9.8±6.56     | 10.5±4.73  | 10.1±4.32  |             |         |
| Prot Nr                             | 19.2±6.62  | 21.4±14.64   | 23.3±19.92 | 21.5±1.88  | <0.001      |
| Max Prot grad                       | 33.5±11.8  | 27.9±18.9    | 23.6±8.72  | 27.3±4.97  | 0.022       |

CPB—cardio pulmonary bypass; IT—isometric time; Resp Ass—respiratory assistance; ICU—intensive care unit; Hos—hospital; Prot Nr—prosthesis number; Max Prot grad-maximal prosthetic gradient

The following diagrams show correlation of PPM with the patient’s age, BMI, BSA, the number of prosthesis, gender.

Figure 1: Correlation between age and the possibility of PPM occurrence. We have an inverse relation between age and EOAi (EOAi<SEPI).
Discussion

This is the first time that the incidence of PPM in aortic valve surgery has been reported in Albania. It is 10.3% for severe PPM and 67.8% for moderate PPM. Pibaro and Dumesnil refers that the incidence of severe PPM varies 2-11% whereas that of moderate PPM 20-70% [2]. In separate studies, the incidence of severe and moderate PPM is referred respectively 2.3% -6.8% and 8.5% -58.7% [8-14].

We note that EOAi values that are taken as point references for the presence or not of PPM were different in various studies and they range from 0.7 -0.85cm² / m². In our study we used traditional point of references: 0.65cm² / m² ≤EOAi<0.85cm² / m² for moderate PPM and EOAi < 0.65 cm² / m² for severe PPM. It seems that in our study group who underwent isolated aortic valve surgery, the PPM incidence is similar to other clinics. It remains an usual phenomenon.

The fact that this is common occurrence opened the debate about its impact on the results of aortic valve surgery. This debate is nowadays still open.

In our study, the majority of the indicators of early operative results such as mortality, low cardiac output, pulmonary complications, bleeding, atrial fibrillation and wound infection have higher incidence with the patient-prosthesis mismatch group compared with the group without this phenomenon. The overall mortality is 3.1% while in the group with severe PPM mortality was 5% in the group with moderate PPM 3.1% and for the group without PPM 2.4%.

Kaminishi et al, in a study, which involved 3609 patients with isolated aortic valve surgery, refer early mortality 2.2% for the group without PPM and 3.9% for the group with PPM. These are similar to our results. Despite mortality in the group with the PPM is greater, this difference is not significant. PPM importantly affects only the duration of stay in intensive care unit and respiratory assistance [8]. Jamienjson et al in a series of 3343 patients concluded that early mortality independent risk factors are age, NYHAIII-IV, simultaneous coronary surgery, type of prosthesis, COPD, renal insufficiency and diabetes mellitus. PPM is not part of the risk factors for early mortality and even more the phenomenon does not affect long-term outcomes [9]. In addition, post-operative complications such as haemorrhage, stroke or complete atria-ventricular block, as well as in our study, are not affected by the presence of PPM [10]. There are also many smaller studies that support these results. In addition, PPM does not affect even the response of left ventricle muscle mass in the long-term follow-up [15]. Results of aortic valve surgery are satisfactory in the presence of 76% incidence of PPM [16].

At the same time, there are many studies, which refer PPM as an important risk factor in early results of aortic valve surgery [11, 13, 16-18]. Walther et al. in a study where were included 4131 patients, of which 1856 used mechanical prosthesis and 2275 biological prosthesis, analyzed the impact of PPM in early mortality of aortic valve surgery. Mortality for each group according to PPM degree was 5.2% in the group with severe PPM, 10.6% in the group with moderate PPM and 6.9% without PPM. Statistical analysis compared group with moderate PPM and without PPM and the difference was significant (p = 0.018). This group clearly concludes that PPM is an important risk factor in early mortality of aortic valve surgery based upon other factors such as emergency surgery, euro score greater than 10, age greater than 70 years old and simultaneous surgical procedures. This study recommended using information on specific prosthesis and specific data for each patient in order to avoid the PPM. In that context, various techniques can be used ranging from aortic valve annulus enlargement to surgery the aortic root [13].

Hernandez et al in a study very similar to this study, noticed that the mortality in the group with PPM was approximately 8.2%, while in the group without PPM, was 0.7%, with significant difference (p = 0.004), while for complications such as acute myocardial infarction, stroke, bleeding, post operative atrial fibrillation, pneumonia, the need for respiratory assistance, there is a tendency to have a higher incidence in the group with PPM and some of these differences are important and similar to this study. In
Conclusion, this group refers PPM as an important negative risk factor in early results in aortic valve surgery [16]. PPM is closely related with hospital mortality and cardiac events [11]. Supporting these findings is the group of Toronto who refer 8% mortality rate for patients with PPM and 5% in the group without MPP (p = 0.003). The last two groups referred to the moderate PPM and recommend the need to prevent the occurrence of PPM [17].

An interesting study that was published by Foster and colleagues, which refer that PPM increases operative mortality not significantly, but PPM impairs importantly muscle mass regress and in conditions when hyper trophy is an important risk factor for mortality, PPM may be a risk factor [14]. Patient-prosthesis mismatch should be analyzed together with patient characteristics. Urso and colleagues in a review associated with the effects of PPM concluded that severe PPM should be always avoided while moderate MPP can be tolerated except in cases of impaired cardiac function [19].

The controversy regarding the impact of early results of prosthesis- patient mismatch will probably continue. In this study, it seems that even PPM is a usual occurrence and does not influence negatively these results. Maybe in the future we will need to study this argument in special groups of patients such as in elderly patients or in patients with important left ventricle dysfunction. Furthermore, to determine the attitude towards PPM, it is very important to study this impact in long-term results of aortic valve surgery.

In conclusion, patient-prosthesis mismatch is a common occurrence in aortic valve surgery. This phenomenon does not affect the early results of aortic valve surgery.

References
1. Rahimtoola ShH. The Problem of Valve Prosthesis-Patient Mismatch. Circulation. 1978;58:20-24. http://dx.doi.org/10.1161/01.CIR.58.1.20
PMid:16251232 PMCID:PMC1861088
2. Pibarot P, Dumensil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart. 2006;92:1022–1029. http://dx.doi.org/10.1136/hrt.2005.067363
PMid:16251232 PMCID:PMC1861088
3. Pibarot P, Dumensil JG. Prosthetic Heart Valves: Selection of the Optimal Prosthesis and Long-Term Management. Circulation. 2009;119 1034-1048 http://dx.doi.org/10.1161/CIRCULATIONAHA.108.778886
PMid:19237674
4. ATS Medical. ATS open pivot standard heart valve. Effective Orifice Area (EOAI) Calculator.
5. Nashef SA, Roques F, Michel P, Gauduchon E, Lemesnev S, Salamon. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothoracic Surg. 1999;16:9–13. http://dx.doi.org/10.1016/S1113-1847(99)00013-4
6. Bonow RO, Carabello BA, Chatterjee K, de Leon ACJr, Faxon DP, Freed MD, Gaasch WH, Llytle BW, Nishimura RA, O’Gara PT, O’Rourke RA. Otto CM, Shah PM, Shaweatitude JS. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC. 2006; 48(3):e1–148. http://dx.doi.org/10.1016/j.jacc.2006.05.021
PMid:16875962
7. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Jung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J. Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-96.
PMid:22922415
8. Kaminishi Y, Misawa Y, Kobayashi J, Konishi H, Miyata H, Motomura N, Takamoto Sh. Patient- prosthesis mismatch in patients with aortic valve replacement. Gen Thorac Cardiovasc Surg. 2013; 61:274–279. http://dx.doi.org/10.1007/s11748-013-0216-6
PMid:23404312 PMCID:PMC3641294
9. Eric Jamieson WR, Ye J Higgins J, Cheung A, Fradet GJ, Skarsgard P, Germann E, Chan F, Lichtenstein S. Effect of Prosthesis-Patient Mismatch on Long-Term Survival With Aortic Valve Replacement: Assessment to 15 Years. V Ann Thorac Surg. 2010;89:51–9. http://dx.doi.org/10.1016/j.athoracsur.2009.08.070
PMid:20103205
10. Kobayashi Y, Fukushima Y, Hayase T, Koijima K, Endo G. Clinical Outcome of Aortic Valve Replacement With 16-mm ATS-Advanced Performance Valve for Small Aortic Annulus. Ann Thorac Surg. 2010;89:1195–9. http://dx.doi.org/10.1016/j.athoracsur.2009.12.074
PMid:20338332
11. Tasca G, Mhagna Z, Perotti S, Centurini PB, Sabatini T, Amaducci A, Brunelli F, Cirillo M, Dalla Tomba M, Quiani E, Troise G, Pibarot P. Impact of Prosthesis-Patient Mismatch on Cardiac Events and Midterm Mortality After Aortic Valve Replacement in Patients With Pure Aortic Stenosis. Circulation. 2006;113:570-576. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.587022
PMid:16401767
12. Howell NJ, Keogh BE, Ray D, Bonser RS, Graham TR Mascaro J, Rooney SJ, Wilson IC, Pagano D. Patient-Prosthesis Mismatch in Patients With Aortic Stenosis Undergoing Isolated Aortic Valve Replacement Does Not Affect Survival. Ann Thorac Surg. 2010;89:60–4. http://dx.doi.org/10.1016/j.jatvs.2009.12.037
PMid:20103206
13. Walther T, Rastan A, Falk V, Lehmann S, Garbade J, Funkat AK, Mohr FW, Gummett JF. Patient prosthesis mismatch affects short- and long-term outcomes after aortic valve replacement European Journal of Cardio-thoracic Surgery. 2006;30:15–19. http://dx.doi.org/10.1016/j.ejcts.2006.04.007
PMid:16730449
14. Fuster RG, Montero Argudo JA, Albaroza OG,Sos FH, Lopez SC, Codoner MB,Buenedia Minano JA, Albarran IR. Patient- prosthesis mismatch in aortic valve replacement: really tolerable? European Journal of Cardio-thoracic Surgery. 2005;27:441–449. http://dx.doi.org/10.1016/j.ejcts.2004.11.022
PMid:15740953
15. Garatti A, Mori F, Innocente F, Canziani A, Gagliardotto P, Mossuto E, Santoro T, Montericco V, Frigiola A, Menicacci L. Aortic Valve Replacement With 17-mm Mechanical Prostheses: Is Patient–Prosthesis Mismatch a Relevant Phenomenon? Ann Thorac Surg. 2011;91:71–8. http://dx.doi.org/10.1016/j.athoracsur.2010.10.036
PMid:21172488
16. Pisano C, D’Amico T, Palmeri C, Franchino R, Fattouch K, Bianco G, Ruvelo G. Valve prosthesis-patient mismatch: hemodynamic, echocardiographic and clinical consequences.
Interactive Cardio Vascular and Thoracic Surgery. 2011;13:606-610.
http://dx.doi.org/10.1510/icvts.2011.283218
PMid:21891800

17. Hernández-Vaquero D, Llosa JC, Díaz R, Khalpey Z, Morales C, López RAJ, Boye F. Impact of patient-prosthesis mismatch on 30-day outcomes in young and middle-aged patients undergoing aortic valve replacement. Journal of Cardiothoracic Surgery. 2012;7:46.
http://dx.doi.org/10.1186/1749-8090-7-46
PMid:22587627 PMCid:PMC3428658

18. Rao V, Eric Jamieson WR, Ivanov J, RN, Armstrong S, David TE. Prosthesis-Patient Mismatch Affects Survival after Aortic Valve Replacement. Circulation. 2000;102:iii-5-iii-9.
http://dx.doi.org/10.1161/01.CIR.102.suppl_3.III-3

19. Hanayama N, Christakis GT, Mallidi HR, Joyner CD, Frenes SE, Christopher D, Morgan CD, R. Mitoff PR, Goldman BS. Patient Prosthesis Mismatch Is Rare After Aortic Valve Replacement: Valve Size May Be Irrelevant. Ann Thorac Surg 2002;73:1822–9.
http://dx.doi.org/10.1016/S0003-4975(02)03582-8

20. Urso Sa Sadaba R, Aldamiz-Echevarría G Is patient-prosthesis mismatch an independent risk factor for early and mid-term overall mortality in adult patients undergoing aortic valve replacement? Interactive CardioVascular and Thoracic Surgery. 2009;9:510–519.
http://dx.doi.org/10.1510/icvts.2009.207597
PMid:19497953